This study expands on prior research by assessing breast cancer-specific mortality among the ER/PR/HER2 subtypes by stage and contrasts the results with a surrogate classification that incorporates the ER/PR/HER2 subtypes as well as tumor grade. This evidence concerns the gene ERBB2 and breast carcinoma.